

Disclaimer

Cautionary statements:

This should be read in conjunction with the documents distributed by Aviva plc (the "Company" or "Aviva") through The Regulatory News Service (RNS). This presentation contains, and we may make other verbal or written "forwardlooking statements" with respect to certain of Aviva's plans and current goals and expectations relating to future financial condition, performance, results, strategic initiatives and objectives. Statements containing the words "believes", "intends", "expects", "projects", "plans", "will," "seeks", "aims", "may", "could", "outlook", "likely", "target", "goal", "guidance", "future", "estimates", "potential" and "anticipates", and words of similar meaning, are forwardlooking. By their nature, all forward-looking statements involve risk and uncertainty. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in these statements. Aviva believes factors that could cause actual results to differ materially from those indicated in forward-looking statements in the presentation include, but are not limited to: the impact of ongoing difficult conditions in the global financial markets and the economy generally; the impact of simplifying our operating structure and activities; the impact of various local and international political, regulatory and economic conditions; market developments and government actions (including those arising from the referendum on UK membership of the European Union); the effect of credit spread volatility on the net unrealised value of the investment portfolio; the effect of losses due to defaults by counterparties, including potential sovereign debt defaults or restructurings, on the value of our investments; changes in interest rates that may cause policyholders to surrender their contracts, reduce the value of our portfolio and impact our asset and liability matching; the impact of changes in short or long term inflation; the impact of changes in equity or property prices on our investment portfolio; fluctuations in currency exchange rates; the effect of market fluctuations on the value of options and guarantees embedded in some of our life insurance products and the value of the assets backing their reserves; the amount of allowances and impairments taken on our investments; the effect of adverse capital and credit market conditions on our ability to meet liquidity needs and our access to capital; changes in, or restrictions on, our ability to initiate capital management initiatives; changes in or inaccuracy of assumptions in pricing and reserving for insurance business (particularly with regard to mortality and morbidity trends, lapse rates and policy renewal rates), longevity and endowments; a cyclical downturn of the insurance industry; the impact of natural and man-made catastrophic events on our business activities and results of operations; our reliance on information and technology and third-party service providers for our operations and systems; the inability of reinsurers to meet obligations or unavailability of reinsurance coverage; increased competition in the UK and in other countries where we have significant operations; regulatory approval of extension of use of the Group's internal model for calculation of regulatory capital under the European Union's Solvency II rules; the impact of actual experience differing from estimates used in valuing and amortising deferred acquisition costs ("DAC") and acquired value of in-force business ("AVIF"); the impact of recognising an impairment of our goodwill or intangibles with indefinite lives; changes in valuation methodologies, estimates and assumptions used in the valuation of investment securities; the effect of legal proceedings and regulatory investigations; the impact of operational risks, including inadequate or failed internal and external processes, systems and human error or from external events (including cyber attack); risks associated with arrangements with third parties, including joint ventures; our reliance on third-party distribution channels to deliver our products; funding risks associated with our participation in defined benefit staff pension schemes; the failure to attract or retain the necessary key personnel; the effect of systems errors or regulatory changes on the calculation of unit prices or deduction of charges for our unit-linked products that may require retrospective compensation to our customers; the effect of fluctuations in share price as a result of general market conditions or otherwise; the effect of simplifying our operating structure and activities; the effect of a decline in any of our ratings by rating agencies on our standing among customers, broker-dealers, agents, wholesalers and other distributors of our products and services; changes to our brand and reputation; changes in government regulations or tax laws in jurisdictions where we conduct business, including decreased demand for annuities in the UK due to proposed changes in UK law; the inability to protect our intellectual property; the effect of undisclosed liabilities, integration issues and other risks associated with our acquisitions; and the timing/regulatory approval impact, integration risk, and other uncertainties, such as non-realisation of expected benefits or diversion of management attention and other resources, relating to announced acquisitions and pending disposals and relating to future acquisitions, combinations or disposals within relevant industries; the policies, decisions and actions of government or regulatory authorities in the UK, the EU, the US or elsewhere, including the implementation of key legislation and regulation. For a more detailed description of these risks, uncertainties and other factors, please see the 'Risk and risk management' section of the strategic report in Aviva's most recent Annual Report. Aviva undertakes no obligation to update the forward looking statements in this announcement or any other forward-looking statements we may make. Forward-looking statements in this presentation are current only as of the date on which such statements are made. This report has been prepared for, and only for, the members of the Company, as a body, and no other persons. The Company, its directors, employees, agents or advisers do not accept or assume responsibility to any other person to who this document is shown or into whose hands it may come, and any such responsibility or liability is expressly disclaimed.



Update from June

	What we said	What we've done		What's next
Organisational design	Separate management structure for UK Life & GI	Separate management teams in place	√	Drive accountability to ensure competitiveness and enhanced performance
Digital	Align with trading business	Digital aligned to UK GI business	√	Leverage digital and insurance expertise, driving commercial outcomes across Aviva
Costs	£300m cost saving by 2022 net of inflation & at constant FX	£25m run-rate savings to date	-	Increase the pace of change Use efficiency to drive competitiveness
Strategy	Full review of group and business unit strategy	Evaluating options for Asia businesses	-	Detailed update in November

Interim results headlines

£1,448m
Operating profit¹,+1%

27.3pOperating EPS, +2%

9.50pDividend, +3%

194%

£0.8bn

Operating capital generation

£2.3bn
Centre liquidity³

Solvency II cover ratio²

Results snapshot

Financial performance

Resilient results in challenging markets, with fewer one-off benefits But mixed performance reinforces importance of improving fundamentals

Fundamentals

Progress on expenses with contractor headcount down 7% in 2Q Separate UK life and UK GI management structures and UK digital moved into UKGI

Financial strength

Solvency II ratio² resilient at 194% and centre liquidity³ strong at £2.3 billion S&P upgrade to AA- reflects continued strength of balance sheet

Interim dividend


9.50 pence per share, +3% Consistent with progressive policy, reflects underlying performance and external environment

Strategy

Evaluating strategic options for our Asia businesses Update on strategic and financial priorities November

Financial performance - operating profit

Life




- Fewer one-off benefits, absence of longevity in H1
- Adverse market impact on fee income
- Lower protection results in UK and France

General insurance & health




- Canadian recovery accelerating
- Benign weather in HY19
- Growth in Commercial Lines
- Higher costs from UK digital

Aviva Investors



- Lower revenues in a weak environment
- Improved investment performance in 2019
- July mandate wins supportive for H2


Group debt, corporate costs & other



- Positive impact from moving UK digital costs into UK GI
- Lower debt costs in the period
- Move to lean group centre underway


Efficiency

Operating expenses



- Operating expenses up 2%, elevated 2H18 baseline flowed into 1H19
- FY expenses expected to be lower than FY18, including implementation costs
- Action taken to stop non-core projects with greater rigour on future project funding approval

£300m run-rate cost target progress



- Transformation team in place, workstreams mobilised
- Targets agreed with leadership teams across markets and functions
- Targeting significant reduction in group centre, material savings within BU's and rationalisation of project and change spend

Running Aviva better

Extending distribution, working closely with our partners...



- Contract wins in UK, Canada, France
- Digital platforms enhancing productivity
- Proactive mix management
- Weekly management trading calls

...building upon our strong technical foundations...



- Taking Quantum expertise global
- Next generation fraud & analytics model
- Granular mortality modelling
- Modern platforms (FNZ) & (Guidewire)


...and delivering a better experience for customers



- "Best of the best insurer" July 2019
- Simplifying customer journeys
- Focused on first contact resolution
- Technology enabling 24/7 accessibility


Capital

Solvency II cover ratio²




- Capital surplus broadly stable at £11.8bn
- Progress on balance sheet strength recognised by S&P with upgrade to AA-

Centre cash³



- £1.6 billion cash inflows to centre
- Centre cash reinforces resilience and provides capacity for deleveraging plan

Dividend



- Interim dividend 9.50p per share, +3%
- Consistent with progressive dividend policy
- Reflects underlying business performance and external environment
 - OCG: £0.8bn, vs £0.9bn in HY18
 - Operating EPS: 27.3p, up 2% YoY
 - Cash: £2.3bn centre liquidity³, priority to deleverage




HY19 snapshot

Operating profit +1%


£m	HY18	HY19	Change
Life	1,392	1,282	(8)%
GI & Health	302	391	29%
Aviva Investors	76	62	(18)%
Corporate costs & other	(148)	(120)	19%
Group debt costs	(184)	(167)	9%
Group operating profit	1,438	1,448	1%

BU operating profit by geography (£m)	HY18	HY19	Change
UK Life	831	722	(13)%
Europe	508	498	(2)%
UK GI & Health	209	187	(11)%
Canada	(12)	98	n/a
Asia (excl. FPI)	47	66	40%
Aviva Investors	76	62	(18)%


Operating EPS +2%



Interim DPS +3%



Stable underlying OCG



SII ratio² 194%



Net asset value


IFRS NAV per share +2%



Net benefit from non-operating items

£m	HY18	HY19
Basic EPS	7.9p	28.2p
Non-operating items included: (gross of tax & MI)		
Market movements	(654)	444
Life	(482)	372
GI & Health	(104)	164
Centre (incl. hedging & FX on centre holdings)	(68)	(92)
AVIF and acquisition-related amortisation	(259)	(235)
Internally generated intangibles amortisation	(52)	(63)

Solvency II position




£bn	31 Dec 2018	BU underlying generation	Debt & Centre costs	Other capital actions	Market, FX and other	2018 final dividend	30 Jun 2019
Own funds	23.6	0.9 NB 0.3 EB 0.6	(0.2)	0.2	0.7	(0.8)	24.4
SCR	(11.6)	0.0 NB (0.4) EB 0.4	-	(0.1)	(0.9)	-	(12.6)

Cash


BU cash remittances of £1.6bn...

- HY19 benefitted from phasing of dividends from UK Life, UKGI, Poland, France and Aviva Investors
- No special dividend in HY19 (HY18: £500m from UK Life)
- Strong cash remittances expected in FY19, albeit lower than FY18 record levels of £3.1bn



...driving Centre Liquidity of £2.3bn

• Strong centre liquidity underpins £1.5bn+ deleveraging plans




Strong balance sheet, low risk asset portfolio

Well-diversified

£93bn shareholder investment assets as at HY19



• £30bn (32%) corporate bonds



• £7bn (8%) commercial mortgage loans



High quality and low risk


- c75% debt securities rated ≥ A
 - More than 90% ≥ BBB
 - c8% rated as investment grade internally
 - <1% below investment grade
- £7bn commercial mortgages
 - Average LTV 56%; loan interest cover 2.75x
 - No loans in arrears
- £8bn non-securitised equity release mortgages
 - Average LTV 26%; average new business LTV 19%
 - House Price Inflation assumption: 0.7% p.a.
- c£8bn PFI and non-PFI infrastructure loans

Prudently positioned

- Well positioned to respond to market fluctuations
 - Above top end of SII working range across all sensitivities
 - Prudent risk management through reinsurance & hedging
 - Actively managing interest rate in France and Italy
- IFRS valuation allowances: £1.8bn for bonds and mortgages; £1.4bn for equity release
- Brexit allowance: stable at £0.4bn
 - 3/4 equity release and 1/4 commercial
 - Equivalent to immediate decrease in property values of 12% for equity release and 14% for commercial
- Pro forma SCR adjustment for potential changes to equity release regulations: stable at £0.2bn

Financial leverage





• Improving leverage: at least £1.5bn debt reduction planned by 2021-22

IFRS S&P debt leverage



Maintaining flexibility in SII regulatory capital with headroom across all tiers

• Continuing to manage leverage consistent with AA ratings

• AA ratings with S&P (July 2019 upgrade), Moody's and Fitch

S&P AA- Stable Moody's Aa3 Stable Fitch AA- Stable

'Neutral' leverage ratio on an S&P basis: 35% as at FY18


Reducing interest cash expense




UK Life

Operating profit -13% *down 1% excl. Legacy/'Other'*

Stable underlying OCG[®]





- HY19 operating performance reflected:
 - £70m lower net one-offs as HY19 didn't benefit from longevity releases
 - Challenging market conditions adversely impacted savings & legacy
 - Stable underlying performance overall despite competitive environment
- £0.9bn cash remitted⁶ (HY18: £0.7bn underlying + £0.5bn special)






- PVNBP⁵ -16% vs. HY18 record BPA trading levels
- New business profit +12% vs. HY18
- Inforce profit -2% (less favourable longevity experience)





- PVNBP⁵ +2%: mix shift towards Group
- Operating profit -4% mainly from lower new business contribution (competitive market impacting Individual sales & margins)


Long-term savings



- Stable net inflows: £1.6bn Platform and £2.0bn Workplace (new wins and improved retention)
- £129bn closing AuA with £26bn Platform AuA


Europe

Operating profit -2%




- Life down 2% with 2018 weak investment markets adversely impacting savings & fee business, and adverse claims experience in Protection in France. This was partly offset by growth in Italy and Friends First acquisition in Ireland
- Stable non-life performance

OCG up, driven by one-offs



- HY19 one-offs: model enhancements in Italy & equity hedging in France; lower underlying OCG post French FRPS implementation and SCR release in 2H18
- Actively managing interest rate exposure in France and Italy
- £0.5bn cash remitted in HY19, reflecting acceleration of dividend payments from Poland & France


Resilient sales and flows



- Stable net flows: £2.4bn driven by Italy (HY18: £2.5bn)
- PVNBP⁵ +9% from Italian hybrid & French WP sales
- NWP +1%: growth in commercial lines partly offset by lower personal motor volumes
- 92.9% GI COR (+0.6pp): +2.8pp variance from benign weather partly offset by large claim costs in France and increased Irish levies


UK GI and Canada

Operating profit +48%



- Benign weather (+£100m HoH) & improved Canadian profitability more than offset lower PY releases overall
- Canada benefitted from rate increases, operational improvements & improved risk selection; on track to reach ≤96% COR by 2020
- £34m adverse earned impact in UKGI from aligning UK Digital (broadly net neutral at group level); 1.6pp adverse impact on HY19 UKGI COR as a result

OCG stable at £0.2bn



- Stable OCG with an improved performance in Canada broadly offsetting the adverse impact of UKD alignment under UKGI
- HY19 cash remittances: £91m UKGI, £15m Canada

Sales and combined ratios

HY18	HY19	Mvt
94.3	95.7	(1.4)pp
104.6	97.5	7.1pp
3.6	3.6	+1%
2.1	2.2	+2%
1.5	1.5	(2)%
	94.3 104.6 3.6 2.1	94.3 95.7 104.6 97.5 3.6 3.6 2.1 2.2

- +7% growth in commercial NWP partly offset by a decline in personal lines
- UKGI COR: 2.8pp benefit from weather vs. LTA (HY18: -0.2pp); +0.8pp PY releases (HY18: +2.0pp)
- Canada COR: 0.4pp benefit from weather vs. LTA (HY18: -2.2pp); +0.3pp PY releases (HY18: -0.5pp strengthening)

£m


Aviva Investors and Asia

Aviva Investors Operating profit (£m) 76 62 HY18 HY19

• Operating profit -18% mainly driven by lower average AuM and revenue loss from disposals in November 2018

- £346bn AuM (FY18: £331bn) driven by £24bn favourable market movements partly offset by £4.9bn net outflows (£0.9bn external, £1.3bn internal core, £2.7bn internal legacy outflows)
- External wins to date in Real Assets and US Credit (\$2.15bn in July)
- Improved performance year to date: 79% of all funds beating benchmark, 53% beating target; AIMS target return up 6.3% year to date
- HY19 £81m cash remittance benefitted from phasing (HY18: £37m)

Asia (excl. FPI)



- Operating profit¹ +40% mainly driven by improved Singapore Health results from remediating actions following underperformance over the past few years
- Continued expansion of Singapore's owned distribution: 1,653 financial advisors at HY19 (FY18: 1,540, +7%)
- China expected to pay first cash remittance in 2H19

Interim results headlines

£1,448m
Operating profit¹,+1%

27.3pOperating EPS, +2%

9.50pDividend, +3%

194%

Solvency II cover ratio²

£0.8bn

Operating capital generation

£2.3bn

Centre liquidity³

Appendix

Earnings per share


Earnings per share

HY	2018	HY 2019
Group operating profit ¹	1,438	1,448
Less operating tax	(303)	(319)
Minority Interest	(46)	(47)
DCI and fixed rate tier 1 notes	(6)	(6)
Preference shares	(9)	(9)
Total operating earnings after tax, MI & DCI and preference shares	1,074	1,067
Weighted average number of shares	4,009	3,907
Operating earnings per share	26.8p	27.3p

Returns

Operating return on total capital employed & return on equity


Group return on capital employed



Group return on equity



Operating return on total capital employed



Analysis of operating return on equity

	Operating profit ¹		Weighted average		
6 months 2019	Before tax	After tax	shareholders' funds incl. NCI	Return on equity %	
United Kingdom Life	722	581	10,100	11.5%	
United Kingdom General Insurance	187	151	1,434	21.1%	
Canada	98	72	1,374	10.5%	
Europe	515	370	5,330	13.9%	
Asia	161	151	1,738	17.4%	
Fund management	61	43	526	16.3%	
Corporate and Other Business ⁸	(123)	(100)	5,848	N/A	
Return on total capital employed	1,621	1,268	26,350	9.6%	
Subordinated debt	(165)	(133)	(6,334)	4.2%	
Senior debt	(8)	(6)	(1,363)	0.9%	
Return on total equity	1,448	1,129	18,653	12.1%	
Less: Non-controlling interests	_	(47)	(972)	9.7%	
Direct capital instrument and tier 1 notes	_	(6)	(730)	4.9%	
Preference capital	_	(9)	(200)	8.5%	
Return on equity shareholders' funds	-	1,067	16,751	12.6%	

Capital & debt

SII own funds by tier

Regulatory view*

HY19	£bn	% of SCR	% of own funds
Tier 1	21.6	133%	77%
T1 unrestricted	19.5	120%	70%
T1 restricted	2.1	13%	7%
Tier 2	6.0	38%	22%
Tier 3	0.4	2%	1%
	28.0	173%	100%

^{*}Estimated


Shareholder view

- Regulatory view of own funds adjusted by £3.6bn due to with-profits funds, pension schemes, notional reset of transitionals and other pro-forma adjustments
- Shareholder view coverage ratio of 194%

SII sensitivities

	Sensitivity	Impact on cover ratio %
Changes in economic assumptions	25 bps increase in interest rate	2%
	50 bps increase in interest rate	4%
	100 bps increase in interest rate	5%
	25 bps decrease in interest rate	(3)%
	50 bps decrease in interest rate	(9)%
	50 bps increase in corporate bond spread ⁹	(3)%
	100 bps increase in corporate bond spread ⁹	(6)%
	50 bps decrease in corporate bond spread ⁹	2%
	Credit downgrade on annuity portfolio ¹⁰	(4)%
	10% increase in market value of equity	2%
	25% increase in market value of equity	4%
	10% decrease in market value of equity	(1)%
	25% decrease in market value of equity	(4)%
Changes in non-economic assumptions	10% increase in maintenance and investment expenses	(7)%
	10% increase in lapse rates	(3)%
	5% increase in mortality/morbidity rates - life assurance	(2)%
	5% decrease in mortality rates - annuity business	(10)%
	5% increase in gross loss ratios	(3)%

Subordinated debt profile




All debt instruments have been presented at optional first call dates at nominal values converted to GBP using 30 June 2019 rates

Balance sheet

Total managed assets

Assets by liabilities covered


£m



Participating assets by type




Shareholder assets by type




Shareholder assets


Shareholder assets by type



Corporate debt by rating




Government debt by rating




Shareholder assets

Corporate bonds by industry




Loans by type




Shareholder assets – mortgage loans

Mortgage loans



Commercial real estate portfolio



Footnotes

- 1. Group adjusted operating profit is a non-GAAP Alternative Performance Measure (APM) which is not bound by the requirements of IFRS. Further details of this measure are included in the 'Other information' section of the Analyst Pack.
- 2. The estimated Solvency II position represents the shareholder view as defined in section 8.i of the Analyst pack.
- 3. Centre liquidity is stated as at end July 2019.
- 4. NAV is presented net of tax & non-controlling interests.
- 5. PVNBP and VNB are presented on an adjusted Solvency II basis.
- 6. Following the UK's decision to leave the European Union, the Ireland branches of the UK business have been transferred to Ireland effective March 2019. As a result, the Ireland business is now reported within Europe instead of the United Kingdom for all metrics. Comparative balances have been restated accordingly.
- 7. In 2018 cash remittances include amounts of £331 million received from UK General Insurance in February 2019 in respect of 2018 activity.
- 8. The Corporate and other business loss before tax of £123 million comprises corporate costs of £97 million, other business operating loss of £70 million, partly offset by interest on internal lending arrangements of £6 million and finance income on the main UK pension scheme of £38 million.
- 9. Credit spread movement for corporate bonds with credit rating A at a 10 year duration, with the other ratings and durations stressed by the same proportion relative to the stressed capital requirement.
- 10. An immediate full letter downgrade on 20% of the annuity portfolio bonds (e.g. from AAA to AA, from AA to A).
- 11. Following a review of the Group's presentation of consolidated investment funds, comparative amounts have been restated from those previously reported. The restatement has had no impact on the profit for the period or equity. See note B2 of the Analyst Pack for further information.